Navigation Links
Study suggests blood test for Alzheimer's possible
Date:3/11/2009

Athens, Ga. Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

Researchers from the University of Georgia, the Charlie Norwood VA Medical Center in Augusta and the Medical College of Georgia compared antibody levels in blood samples from 118 older adults with the participant's level of dementia. The team, whose results appear in the current edition of Journal of Gerontology: Medical Sciences, found that the concentration of two specific proteins that are involved in the immune response increases as the severity of dementia increases.

"We found a strong and consistent relationship between two particular antibodies and the level of impairment," said study co-author L. Stephen Miller, professor and director of clinical psychology training in the UGA Franklin College of Arts and Sciences. "The finding brings us closer to our ultimate goal of developing a blood test that can diagnose Alzheimer's disease or potentially identify if someone is at higher risk for the disease."

Miller's co-authors include Jennifer S. Wilson, a former undergraduate student in the UGA Honors program who is now pursing graduate studies at Emory University; Shyamala Mruthinti, research pharmacologist at the VA Medical Center and adjunct professor at MCG; and Jerry Buccafusco, director of the MCG Alzheimer's Research Center. The team focused on antibodies that the body creates in response to two proteins that are associated with Alzheimer's disease. One protein, known as amyloid-beta, forms the plaques that are evident in the brains of people with Alzheimer's upon autopsy. The other protein, known as RAGE, is involved in the normal aging process but is expressed at higher levels in the brains of people with Alzheimer's.

In a previous study that compared a group of people with Alzheimer's disease to a healthy control group, Mruthinti and her colleagues found that anti-amyloid beta and anti-RAGE antibodies are significantly higher in the group with Alzheimer's. The team's latest study expands on that finding to reveal a direct relationship between severity of Alzheimer's disease and levels of the two antibodies in the blood.

"Alzheimer's is an inflammatory disease of the brain, and these two antibodies give us a way to measure that inflammation," Mruthinti said. "Using them as an early diagnostic marker may allow us to start drug treatment early, when it's most effective, to increase the patient's quality of life."

While optimistic about their findings, the researchers caution that it could still be years before a diagnostic test based on their work is clinically available. The study found that the relationship between the two antibodies and Alzheimer's severity persists even after controlling for patient age and total antibody levels. To further test the strength of the relationship, the researchers are now working with a sample that controls for other factors that have the potential to influence levels of the two antibodies, such as diabetes and heart disease. Buccafusco and his colleagues are also working to decrease the cost and time involved in the test.

"We're in the process of trying to reduce the test to a one-day procedure, whereas right now it takes three to four days," Buccafusco said. "But even now, our test is orders of magnitude cheaper than having people come in every few months to get a functional MRI or PET scan to try to discern brain plaques."

The team is targeting the two proteins themselves as a possible treatment for Alzheimer's disease. Mruthinti explains that, individually, amyloid-beta and RAGE proteins don't provoke an immune response. The trouble begins when the two bind and the immune system attacks, resulting in constant state of inflammation that damages the brain. The researchers recently developed a way to measure levels of amyloid beta-RAGE complex, and preliminary data using transgenic mice that express Alzheimer's symptoms suggest that an antigen they created to boost the body's natural immune response to the complex can reduce the formation of the brain plaques.

"The amyloid beta-RAGE complex cuts off the connections between neurons," Mruthinti explained, "but our hope is that we can protect those connections by preventing those plaques from forming."


'/>"/>

Contact: Sam Fahmy
sfahmy@uga.edu
706-542-5361
University of Georgia
Source:Eurekalert

Related medicine news :

1. Study finds cannabis use, dangerous driving behaviors interrelated
2. Study of 160,000 Medicare Patients Shows Hispanics Have Greater Costs for End-of-Life Care
3. Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
4. UM study reveals demographic trend of the Jewish population in Broward County
5. Shootings Linked to Alcohol-to-Go Outlets, Study Finds
6. Study shows that maintenance rituximab is useful for advanced indolent lymphoma
7. Study Links Blood Type and Pancreatic Cancer
8. New study identifies risk factors in severity of flat head syndrome in babies
9. New Study Shows That One-Third of Shelter Youth Have Been Institutionalized; Almost One-Half Suffered Violence in the Home
10. Beaumont Launches 1st U.S. Adult Human Stem Cell Study for Stress Urinary Incontinence
11. Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... MadgeTech will be showcasing its line of data logging ... at the MadgeTech headquarters. With products sold in more than 100 countries around the ... NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... be offering campers a multitude of activities from daily practices, arts & crafts, ... , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... Petaluma, Ca (PRWEB) , ... May 26, 2016 ... ... joined the organization to provide strategic sales leadership and to further develop their ... holds a B.S. in Business Administration with a concentration in Marketing and an ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... 24, 2016  NxStage Medical, Inc. (Nasdaq: ... advancing renal care, today announced that Jeffrey H. ... the following schedule of investor conferences. Where applicable, a ... http://ir.nxstage.com/ .   ... NY, NY           Friday, June 10, 2016 1:30 p.m. ...
(Date:5/24/2016)... The innovator of COMBO ... s first dual therapy stent, introduces catheters for ... OrbusNeich, a global company specializing in the provision of ... products to treat peripheral artery disease. The JADE™ and ... for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology: